Compliance Rate
Compliance Rate
33.33%
Compliant submissions
1
Incompliant submissions
2
Total trials
3
My Organizations' Clinical Trials
Showing 375 of 788 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/02/24
End: 12/02/24
Due: 12/02/25
Phase: N/A
Priority: Normal
Start: 05/31/06
End: 08/31/07
Due: 08/31/08
Phase: N/A
Priority: Normal
Start: 07/31/16
End: 11/07/17
Due: 11/07/18
Phase: N/A
Priority: Normal
Start: 02/11/22
End: 08/31/25
Due: 08/31/26
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 05/31/13
Due: 05/31/14
Phase: N/A
Priority: Normal
Start: 06/29/15
End: 06/29/16
Due: 06/29/17
Phase: N/A
Priority: Normal
Start: 04/30/13
End: 03/31/16
Due: 03/31/17
Phase: N/A
Priority: Normal
Start: 02/08/21
End: 04/05/25
Due: 04/05/26
Phase: N/A
Priority: Normal
Start: 11/15/21
End: 10/31/25
Due: 10/31/26
Phase: N/A
Priority: Normal
Start: 10/31/04
End: 06/30/11
Due: 06/30/12
Phase: N/A
Priority: Normal
Start: 05/06/21
End: 04/01/22
Due: 04/01/23
Phase: N/A
Priority: Normal
Start: 02/16/24
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 12/18/20
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 08/31/11
Due: 08/31/12
Phase: N/A
Priority: Normal
Start: 08/31/98
End: 01/31/00
Due: 01/31/01
Phase: N/A
Priority: Normal
Start: 07/31/07
End: 08/31/11
Due: 08/31/12
Phase: N/A
Priority: Normal
Start: 06/30/10
End: 07/31/14
Due: 07/31/15
Phase: N/A
Priority: Normal
Start: 07/23/20
End: 06/04/21
Due: 06/04/22
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 12/31/16
Due: 12/31/17
Phase: N/A
Priority: Normal
Start: 04/30/11
End: 08/31/16
Due: 08/31/17
Phase: N/A
Priority: Normal
Start: 09/30/96
End: 08/31/08
Due: 08/31/09
Phase: N/A
Priority: Normal
Start: 05/04/16
End: 03/09/20
Due: 03/09/21
Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
Phase: N/A
Priority: Normal
Start: 09/30/00
End: 11/30/08
Due: 11/30/09
Phase: N/A
Priority: Normal
Start: 03/28/19
End: 12/05/19
Due: 12/05/20
Phase: N/A
Priority: Normal
Start: 02/29/96
End: -
Due: -